New data for liraglutide in type 2 diabetes

Findings from a clinical trial comparing  liraglutide 1.8mg (Victoza) and sitagliptin (100mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions versus continuing with sitagliptin treatment in adults with type 2 diabetes.  These results from the LIRA-SWITCH trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US. The 26-week LIRA-SWITCH trial assessed the efficacy and safety of liraglutide  as an add on to metformin in 407 adults with type 2 diabetes who switched from sitagliptin. Of the 407 adults uncontrolled on sitagliptin (HbA1c 7.5–9.5%) at week 26, those who switched to liraglutide  (n=203) achieved a superior reduction in HbA1c versus those who continued